Viatris Inc
VTRS: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$31.00 | Ygvhs | Pjxmrtwd |
Viatris: Focusing on Complex Injectables and Specialty Therapeutic Areas for Future Growth
We are establishing a fair value estimate of $13 per share for Viatris we don't believe Viatris has created an economic moat. Our forecast lies on a low-single-digit top-line growth and a slight improvement in operating margin over our model period from new branded drugs and complex generics launches offsetting pressures found in its core portfolio.